Auto saved by Logseq

master
Borja Robert 12 months ago
parent ac03d235ad
commit e25e5d21ad

@ -0,0 +1 @@
alias:: albendazole

@ -31,9 +31,9 @@ date:: [[2023/12]]
- Reference lab
- Samples should be run on site (Kato Katz in the schools) and others in-country (ELISA dried blood spots for [[Strongyloides]]), with a lab in Accra still to be identified.
- ##### Communication & Social mobilization - NTD Programme/ [[GHS/RDD]]/Health Promotion/Mundo Sano
- Frame messaging on why doing clinical trial as based on [[Trichuris trichiura]] burden evidence for clinical trial most clear as albendazole is less effective and we have decent burden data; Reinforce messaging that will be a clinical trial, building on and using MDA architecture as much as possible
- GHS to review external communications plan Tuesday 19th
- All/Mundo Sano facilitate
- Frame messaging on why doing clinical trial as based on [[Trichuris trichiura]] burden evidence for clinical trial most clear as [[albendazole]] is less effective and we have decent burden data; Reinforce messaging that it will be a clinical trial, building on and using MDA architecture as much as possible
- [[GHS]] to review external communications plan Tuesday 19th
- All/ [[Mundo Sano]] facilitate
- Circulate and review materials from past MDA and/or relevant trials from communications/social mobilization (GHS has already circulated)
- Align on targeted changes for Ghana and for Kenya (meeting with Kenya scheduled for December 19th with the Comms team)
- Consider how to reflect non-STH diseases also addressed by the FDC (e.g. Onchocercosis, Limphatic Filariasis, Scabies). This was consulted with the Comms team an we are not sure it is a good idea. Perhaps we can think about doing posters and material to be left to the sites after the project, but not during the study, to avoid confussion.

Loading…
Cancel
Save